Exelixis
Exelixis is a multi-platform cancer company dedicated to creating treatment regimens that challenge the status quo and bring us closer to a potential cure, with a focus on innovation in oncology drug discovery, development, and commercialization. Their mission is to help cancer patients recover stronger and live longer through scientific excellence, strategic collaborations, and a commitment to patients and society.
Industries
Nr. of Employees
large (251-1000)
Exelixis
1851 Harbor Bay Parkway Alameda, CA 94502
Patents
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US-12275706-B2
View DetailsCrystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US-12227481-B2
View DetailsProcesses for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US-12128039-B2
View Details
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US-12275706-B2
View DetailsCrystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US-12227481-B2
View DetailsProcesses for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US-12128039-B2
View DetailsProducts
Small-molecule multi-kinase inhibitor (cabozantinib)
An approved small-molecule multi-tyrosine kinase inhibitor developed and commercialized for multiple cancer indications; used as a backbone in combination clinical programs.
Next-generation tyrosine kinase inhibitor (zanzalintinib / XL092)
A next-generation small-molecule tyrosine kinase inhibitor in pivotal and early-phase clinical programs, evaluated both as monotherapy and in combination with immunotherapies.
Investigational targeted small molecules (e.g., USP1 inhibitor)
Early‑phase small‑molecule inhibitors targeting novel oncology targets such as USP1, undergoing Phase 1 evaluation.
Biotherapeutic development candidates (monoclonal antibodies, bispecifics, ADCs)
A portfolio of investigational biologics including monoclonal antibodies, bispecific formats and ADC candidates at discovery and early clinical stages.
Small-molecule multi-kinase inhibitor (cabozantinib)
An approved small-molecule multi-tyrosine kinase inhibitor developed and commercialized for multiple cancer indications; used as a backbone in combination clinical programs.
Next-generation tyrosine kinase inhibitor (zanzalintinib / XL092)
A next-generation small-molecule tyrosine kinase inhibitor in pivotal and early-phase clinical programs, evaluated both as monotherapy and in combination with immunotherapies.
Investigational targeted small molecules (e.g., USP1 inhibitor)
Early‑phase small‑molecule inhibitors targeting novel oncology targets such as USP1, undergoing Phase 1 evaluation.
Biotherapeutic development candidates (monoclonal antibodies, bispecifics, ADCs)
A portfolio of investigational biologics including monoclonal antibodies, bispecific formats and ADC candidates at discovery and early clinical stages.
Services
Sponsorship and operational management of global clinical trials across Phases 1–3, including randomized pivotal studies and investigator-sponsored trial coordination.
Assessment and facilitation of early access requests via Expanded Access Programs, single-patient INDs and named‑patient processes in accordance with applicable regulations.
Partner identification, licensing, co-development and commercialization agreements to advance discovery programs and marketed assets globally.
Sponsorship and operational management of global clinical trials across Phases 1–3, including randomized pivotal studies and investigator-sponsored trial coordination.
Assessment and facilitation of early access requests via Expanded Access Programs, single-patient INDs and named‑patient processes in accordance with applicable regulations.
Partner identification, licensing, co-development and commercialization agreements to advance discovery programs and marketed assets globally.
Expertise Areas
- Oncology clinical development
- Small-molecule drug discovery
- Biotherapeutics and antibody engineering
- Antibody-drug conjugate development
Key Technologies
- Small-molecule tyrosine kinase inhibitors
- Next-generation small-molecule inhibitors (e.g., USP1 inhibitors)
- Monoclonal antibodies
- Bispecific antibody formats